All Updates

All Updates

icon
Filter
Funding
Artera launches with USD 90 million in funding
Precision Medicine
Mar 21, 2023
This week:
Management news
Funding
Minze Health raises USD 5.3 million in funding for product and market expansion; appoints new VP
Preventive Healthcare
Yesterday
Partnerships
Firefly Aerospace partners with True Anomaly for Space Force rapid-response mission launches
Space Travel and Exploration Tech
Yesterday
Funding
zkPass raises USD 12.5 million in Series A funding
Enterprise Blockchain Solutions
Yesterday
Partnerships
Ontada partners with Microsoft to process unstructured oncology data using Azure AI
Clinical Trial Technology
Yesterday
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Product updates
LatticeFlow launches the first evaluation framework for EU AI Act compliance
Generative AI Infrastructure
Yesterday
Precision Medicine

Precision Medicine

Mar 21, 2023

Artera launches with USD 90 million in funding

Funding

  • Bioinformatics company Artera announced its launch with USD 90 million in funding. Johnson & Johnson, TIME Ventures, Koch Disruptive Technologies, Coatue, Walden Catalyst Ventures, The Factory, and Breyer Capital participated in the round, alongside 11 angel investors. 

  • In addition to developing tests that help tailor treatment options for other types of cancer, the funds will be used to disseminate the company's prostate cancer test, both domestically and internationally.

  • California-based Artera is a precision medicine company that is working on AI tests with the aim of customizing treatment options for patients suffering from cancer. The company’s flagship test is the ArteraAI Prostate Test, which is a test to identify patients that will benefit from therapy intensification and help guide treatment decisions for men with localized prostate cancer. The test is clinically available through a single CLIA-certified laboratory in Jacksonville, Florida, and costs USD 3,873.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.